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The role of T H 17 cells in cancer is being investigated but the existence of tumor antigen-specific T H 17 cells has yet to be ascertained. Here 
Introduction
T H 17 cells have been recently defined as a distinct subset involved in the pathogenesis of inflammatory autoimmune diseases, but also in host protection against extra-cellular bacteria, fungi and protozoa (1) . Consistent with a physiologic role of T H 17 in protecting mucosal surfaces such as the gut, lungs and skin, the subset has been shown to be prevalent at these locations (2) 
Materials and methods

Patients samples and cell sorting
Peripheral blood samples were collected from lung cancer patients seen at the 
Results and Discussion
The human tumor antigen MAGE-A3, of the cancer/testis antigen group (13) , is frequently expressed in lung cancers (14) and a MAGE-A3-based anti-cancer vaccine is currently being evaluated in lung cancer patients (15) . We assessed circulating lymphocytes from 38 lung cancer patients (Supplementary Table S2 Fig. 3C and D) . Expression of T-bet was inversely correlated with that of RORγt and was instead higher in the CXCR3 + fractions.
To further clarify the relationship between the identified MAGE-A3-specific populations, we assessed their fine specificity. We initially assessed total CD4 + T cells with MAGE-A3 peptides and detected reactivity against 3 peptides, 141-160, 241-260 and 271-290 (Fig. 4A) Fig. S1A and B) . In addition to recognizing peptide MAGE-A3 141-160, the clones recognized autologous DC incubated with a recombinant MAGE-A3 protein but not with a control protein ( Supplementary Fig. S1C ). TCR analysis of the clones using anti-TCR Vβ mAb revealed that they all used Vβ2 (data not shown) and molecular analysis of the TCR β chain mRNA from 7 clones using specific primers further confirmed that they used the T-cell receptor beta variable gene (TRBV) 20-1, showed that they all used a unique T-cell receptor beta joining gene (TRBJ) and displayed an identical CDR3β (Supplementary Fig. S1D ). 
